2019
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O’Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals Of Oncology 2019, 30: 1842. PMID: 31407010, PMCID: PMC6927326, DOI: 10.1093/annonc/mdz215.Peer-Reviewed Original Research
2016
LBA1_PR breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, Campone M, Blackwell K, André F, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Souami F, Miller M, Germa C, O'Shaughnessy J. LBA1_PR breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Annals Of Oncology 2016, 27: vi553. DOI: 10.1093/annonc/mdw435.03.Peer-Reviewed Original Research
2006
Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons
Burstein H, Mayer E, Partridge A, O'Kane H, Litsas G, Come S, Hudis C, Goldstein D, Muss H, Winer E, Garber J. Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons. Clinical Breast Cancer 2006, 7: 158-161. PMID: 16800976, DOI: 10.3816/cbc.2006.n.026.Peer-Reviewed Original ResearchConceptsResidual ovarian functionAromatase inhibitorsAI therapyBreast cancerMenopausal statusOvarian functionEarly-stage breast cancerInadvertent useChemotherapy-related amenorrheaTreatment-related amenorrheaImportant adjunctive therapyPostmenopausal womenPremenopausal womenAdjunctive therapyOvarian reserveTherapyCancerWomenAmenorrheaPatientsInhibitorsStatusCliniciansHormoneCases